Severe early childhood caries: a modern (neglected) epidemic?
Authors: Schluter PJ, et al.
Summary: The rate of severe early childhood dental caries was investigated in a retrospective analysis of routine oral health data collected from 10,766 children aged 5 years attending the Canterbury DHB child oral health services between 1 January 2018 and 31 December 2019. Overall, 18.4% of children were classified as having severe early childhood caries. Rates were significantly different across ethnic groups with 26.2% in Māori children, 40.1% in Pacific children and 15.4% in non-Māori /non-Pacific children (p<0.001). The authors commented that the heavy oral health burden is unequally shared and the consequences have significant health and wellbeing implications, both now and in the future.
Reference: N Z Med J. 2020;133(1518):10-18.
Abstract
Ethnic inequality in non-steroidal anti-inflammatory drug-associated harm in New Zealand
Authors: Tomlin A, et al.
Summary: Ethnic disparities in the risk of NSAID-associated complications were assessed in a retrospective
cohort study of the primary care population in New Zealand who were dispensed NSAIDs between 2008
and 2015. The risk of hospital admission for upper GI bleeding, heart failure and acute kidney failure in the
90-day period following NSAID dispensing was assessed using national pharmaceutical dispensing and hospital
admissions data. NSAIDs were dispensed to 3,023,067 patients between 2008 and 2015 with a total intended
duration of treatment of 2,353,140 patient-years. Māori patients dispensed NSAIDs were significantly younger
than European patients (p<0.001). Māori patients were more likely than European patients to be hospitalised
for NSAID-associated complications with rate ratios of 2.54 for upper GI bleeding, 2.48 for heart failure and
1.46 for acute kidney failure. The higher risk of upper GI bleeding and heart failure in Māori patients was most
evident in males and patients aged <60 years. The authors commented that interventions promoting safer use
of NSAIDS are needed to reduce the inequity in serious complications across ethnic groups.
Reference: Pharmacoepidemiol Drug Saf. 2020;29(8):881-889.
Abstract